Last reviewed · How we verify
UTD1 Injection plus capecitabine
UTD1 Injection plus capecitabine works by targeting and inhibiting the action of certain enzymes involved in DNA synthesis, thereby inhibiting cancer cell growth.
UTD1 Injection plus capecitabine works by targeting and inhibiting the action of certain enzymes involved in DNA synthesis, thereby inhibiting cancer cell growth. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | UTD1 Injection plus capecitabine |
|---|---|
| Sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
| Drug class | Chemotherapy |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
UTD1 Injection is a chemotherapy medication that targets and inhibits the action of thymidylate synthase, an enzyme involved in DNA synthesis. Capecitabine is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA, causing DNA damage and inhibiting cancer cell growth. The combination of UTD1 Injection and capecitabine is used to treat various types of cancer.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases (PHASE2)
- Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |